Target List
Covers specific sides of specific exons of the targeted genes based on the Human GRCh38 genome build.Analyzes the expression of the targeted genes.Covers specific hotspots of the targeted genes based on the Human GRCh38 genome build.
Acute Lymphoblastic Lymphomas
CREBBP (CBP), KMT2A, MLLT10, MYC, P2RY8, PRDM16, STIL
Anaplastic Large Cell Lymphomas
ADGRG7, ALK, ATIC, CLTC, MSN, MYC, NPM1, TFG, TPM3, TPM4, ALK, CDKN2A (P16INK4A), DNMT3A, NRAS, STAT3
Angioimmunoblastic T Cell Lymphomas
CD28, CTLA4, FIP1L1, PDGFRA, ALK, APC, ARID1A, ASXL1, ATM, BRAF, CDKN2A (P16INK4A), CREBBP (CBP), CTNNB1, DNMT3A, EZH2, FBXW7, IDH2, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MED12, PLCG1, RHOA, STAT3, WT1, XPO1, ZFHX3
Burkitt Lymphomas
BCL6, MYC, PBX1, TCF3, APC, ARID1A, ATM, CD79B, CDKN2A (P16INK4A), CREBBP (CBP), FBXW7, HLA-A, ID3, KRAS, MYC, MYD88, NRAS, PAX5, PIK3CA (p110-alpha), PIK3R1 (p85-ALPHA), PTEN, RHOA, SRSF2
Diffuse Large B Cell Lymphomas (DLBCL)
ALK, BCL11A, BCL6, CCND3, CIITA, CLTC, IGLL5, MAPK13 (p38delta), MYC, NPM1, PIM1, REL, SQSTM1, TBL1XR1, TOMM40, TP63, ALK, AMER1, APC, ARID1A, ASXL1, ATM, B2M, BCL2, BCOR, BRAF, BTK, CD79B, CDKN2A (P16INK4A), CNOT3, CREBBP (CBP), CTNNB1, CXCR4, DNMT3A, EZH2, FBXW7, HLA-A, ID3, IDH2, IRS4, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MAP2K1, MED12, MSN, MYC, MYD88, NCOR1, NFKBIE, NOTCH2, NRAS, NSD2, PAX5, PIK3CA (p110-alpha), PIK3R1 (p85-ALPHA), PLCG1, POT1, PPM1D, PTEN, RGS7, RHOA, SF3B1, SMO, SRSF2, STAT3, STAT5B, STAT6, TERT, TRRAP, WT1, XPO1, ZFHX3, ZNF479
Follicular Lymphomas
AFF3, BCL2, BCL6, CIITA, MYC, TBL1XR1, TP63, AMER1, ARID1A, ATM, B2M, BCL2, BCOR, BRAF, BTK, CD79B, CDKN2A (P16INK4A), CREBBP (CBP), CXCR4, DNMT3A, EZH2, FBXW7, ID3, IDH2, KMT2D, MAP2K1, MED12, MYD88, NOTCH2, NRAS, PIK3R1 (p85-ALPHA), PPM1D, PTEN, RGS7, RHOA, SRSF2, STAT6, ZMYM3
Hodgkin Lymphomas
ALK, CIITA, JAK2, NPM1, SEC31A, ARID1A, ASXL1, B2M, BCOR, CDKN2A (P16INK4A), DNMT3A, EZH2, NFKBIE, NRAS, PAX5, PIK3R1 (p85-ALPHA), PPM1D, SF3B1
Inflammatory Myofibroblastic Tumors
ALK, DCTN1
Lymphoblastic Lymphomas
BCR, ETV6, FGFR1, NOTCH1, PBX1
Lymphoblastic T Cell Lymphomas
BCR, ETV6, FGFR1, FIP1L1, LYN, PDGFRA
Mantle Cell Lymphomas
CCND3, MYC, ARID1A, ASXL1, ATM, B2M, BCOR, BRAF, BTK, CDKN2A (P16INK4A), CREBBP (CBP), DNMT3A, IDH2, KMT2D, KRAS, MED12, NCOR1, NFKBIE, NOTCH2, NRAS, NSD2, PAX5, POT1, PPM1D, PTEN, STAT3, TERT, ZFHX3
Mediastinal Large B Cell Lymphomas (MLBL)
CIITA, PDCD1LG2
Mediastinal Large B-Cell Lymphomas
CIITA, PDCD1LG2
Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas
BCL6, BIRC3 (c-IAP2), CCND3, MALT1, MYC, MYD88, NOTCH2
Peripheral T Cell Lymphomas
ALK, ETV6, FGFR3, ITK, MYO1F, NPM1, S100A7, SYK, TBL1XR1, THAP4, TP63, VAV1, ALK, ARID1A, ASXL1, ATM, CDKN2A (P16INK4A), CTNNB1, DNMT3A, IDH2, IRS4, KIT (CD117), KMT2D, KRAS, MAP2K1, MSN, NRAS, PLCG1, PTEN, RGS7, RHOA, STAT3, STAT5B, TRRAP, XPO1, ZFHX3, ZNF479
Precursor T Cell Lymphoblastic Lymphomas
ABL1, JAK2, NUP214, PCM1, SET, CTNNB1, FBXW7, NRAS, WT1
T Cell Lymphomas
ATXN2L, FGFR1, JAK2
Other Lymphomas
ALK, ATXN2L, BCL6, BIRC3 (c-IAP2), CBFB, CCND1, CCND3, CDK6, CHIC2, CLTC, DEK, DUSP22, EIF4A1, JAK2, KMT2A, MALT1, MKL1, MLF1, MLLT10, NFKB2, NPM1, PRDM16
Commercial Control Samples
ALK, BAIAP2L1, BRAF, CCDC6, CD74, EGFR (ERBB1), EML4, ERG, ETV6, FGFR3, KIF5B, LMNA, MET, NCOA4, NTRK1, NTRK3, PAX8, PPARG, RET, ROS1, SEPT14, SLC34A2, SLC45A3, TACC3, TFG, TMPRSS2, TPM3
Checkpoint Molecules
Inhibitory on Tumor Cells
CD200, CD274 (PD-L1), CD274 (PD-L1), CD48, CD80, CD86, ITGAV, ITGB3, LGALS9, MICA, MICB, PDCD1LG2, TNFRSF14, VSIR
Stimulatory on Tumor Cells
CD40 (TNFRSF5), CD40LG, CD48, CD70, CD86, ICOSLG, TNFRSF9, TNFSF14, TNFSF4 (OX40L), TNFSF9
Inhibitory on T Cells
BTLA, CD160, CD200R1, CD244, CD274 (PD-L1), CD274 (PD-L1), CD28, CTLA4, HAVCR2, KLRC1, LAG3, LILRB1, LILRB3, PDCD1 (PD1), PDCD1 (PD1), VSIR
Stimulatory on T Cells
CD244, CD27 (TNFRSF7), CD28, CD40 (TNFRSF5), CD40LG, ICOS, TNFRSF14, TNFRSF18, TNFRSF4 (OX40), TNFRSF9, TNFSF14, TNFSF9
T Cell Receptor Genes
CD247, CD3D, CD3E, CD3G, TRAC, TRGC2
Major Histocompatibility Complex I Genes
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1
Major Histocompatibility Complex II Genes
CD74, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
Other Checkpoint Molecules
ADORA2A, BTNL2, CD160, CD276, CD44, CD52, CD8A, HHLA2, IDO1 (IDO), IDO1 (IDO), IDO2, KIR3DL1, KLRD1, LAIR1, MS4A1, NRP1, TIGIT, TMIGD2, TNFRSF25 (DR3), TNFRSF8, TNFSF15, VTCN1
Checkpoint Blockade Therapy Biomarkers
BTLA, CD274 (PD-L1), CD274 (PD-L1), CD80, CD8A, CSF2 (GM-CSF), CXCL11 (I-TAC, IP-9), HAVCR2, HLA-DRA, HLA-DRB1, HLA-DRB5, ICOS, IFNG, LAG3, PDCD1 (PD1), PDCD1 (PD1), PDCD1LG2
Immuno Regulatory Gene Signature
ERBB2 (HER-2, NEU), FAS, IL5RA (CD125), INHBA, TNFRSF8, TNFSF4 (OX40L), TNFSF9
Immuno Stimulatory Gene Signature
CD160, CD19, CD200, CD27 (TNFRSF7), CD44, CTLA4, HLA-A, IL12RB2, IL17A, KIT (CD117), TNFRSF17
Immuno Suppressive Gene Signature
CD274 (PD-L1), CD274 (PD-L1), CD276, HAVCR2, PDCD1LG2, TGFB1
Upregulated in Cancer Vaccination Response
CCL5 (RANTES), CD3D, CD86, CD8A, CXCL10 (INP10), CXCL9 (MIG), GBP1, ICOS, IRF1, KLRD1, PSMB9, STAT1
Immune Cell Markers
CD8 T Cells
CD8A, CD8B, FLT3LG, GZMM, PRF1
Th1 Cells
CCL4 (MIP-1B), CD38, CD70, CSF2 (GM-CSF), CTLA4, DPP4, IFNG, IL12RB2, LTA (TNFB), STAT4, TBX21
Th17 Cells
IL17A, IL17RA, RORC
Th2 Cells
CXCR6, GATA3, IL26, LAIR2, MAF, PMCH, SMAD2 (MADH2), STAT6
Follicular Helper T Cells
BCL6, CXCL13, MAF, PDCD1 (PD1), PDCD1 (PD1)
Other T Helper Cell Markers
ANP32B, BATF, CD28, ICOS, NUP107
Regulatory T Cells
FOXP3
Gamma Delta T Cells
CD160, FEZ1, TRGC1
Central Memory T Cells
ATM, DOCK9, FYB1, NEFL, REPS1, TXK, USP9Y
Effector Memory T Cells
AKT3, CCR2, EWSR1, IL15RA, LTK, NFATC4 (NFAT3)
Other T Cell Markers
CD2, CD247, CD3D, CD3E, CD3G, CD6, IL2RB, TNFRSF25 (DR3), TRAC, TRGC2
Myeloid Derived Suppressor Cells
TGFB1
Cytotoxic Lymphocytes
CD3E, CD3G, CD8A, CD8B, EOMES, GZMA, GZMB, IFNG, KLRC1, KLRD1, NKG7, TBX21
Natural Killer Cells
BCL2, CD160, FOXJ1, FUT5, GTF3C1, GZMB, IL21R, KIR3DL1, MPPED1, NCR1, PLA2G6, RRAD, ZNF205
Activated Dendritic Cells
CCL1 (I-309), EBI3, LAMP3, OAS3
Immature Dendritic Cells
CD1A, CD1B, CD1E, F13A1, SYT17
Myeloid Dendritic Cells
CD1A, CD1B, CD1E
Plasmacytoid Dendritic Cells
IL3RA
Other Dendritic Cell Markers
CCL13 (MCP-4), CCL17 (TARC), CCL22 (MDC), CD209, HSD11B1
Macrophages
APOE, CCL7 (MCP-3), CD68, CHIT1, CXCL5 (ENA-78, LIX), MARCO, MSR1
Neutrophils
CSF3R (GM-CSFR), FPR2, MME
Eosinophils
CCR3, IL5RA (CD125), PTGDR2 (CRTH2, GPR44), SMPD3, THBS1 (TSP-1)
Mast Cells
CMA1, CTSG, KIT (CD117), MS4A2, PRG2, TPSAB1
B Cells
BANK1, BLK, CD19, CD79A, CR2, HLA-DOB, HLA-DQA1, MS4A1, PAX5, TNFRSF17
Antigen Presenting Cells
CMKLR1
Regulatory T Cell Gene Signature
CD274 (PD-L1), CD274 (PD-L1), JAK1, PDCD1LG2, TIGIT, TNFRSF18, TNFRSF4 (OX40), TNFRSF8, TNFRSF9
T Cell Trafficking & Infiltration into Tumors
Stimulates T Cell Trafficking & Infiltration into Tumors
CCL5 (RANTES), CX3CL1, CXCL10 (INP10), CXCL9 (MIG), ITGB2, SELL (LECAM-1)
Other T Cell Trafficking & Infiltration into Tumors Genes
CCL17 (TARC), CCL4 (MIP-1B), CCR3, CCR6, CD274 (PD-L1), CD274 (PD-L1), CD44, CSF2 (GM-CSF), CXCL11 (I-TAC, IP-9), CXCL13, FOXP3, IFNG, ITGA4 (CD49D), ITGB7, LTA (TNFB), PDCD1 (PD1), PDCD1 (PD1), PDCD1LG2, PTEN, TNFRSF25 (DR3), TNFSF14
T Cell Exhaustion
Upregulated in T Cell Exhaustion
CCL5 (RANTES), CD200, CD27 (TNFRSF7), CD69, CTLA4, CXCL10 (INP10), CXCL13, GBP1, HLA-DMA, HLA-DQA1, ICOS, IFI16, IFNG, ITGAV, TAP1 (ABCB2), TIGIT, TNFRSF9
Downregulated in T Cell Exhaustion
TNFRSF25 (DR3)
T Cell Exhaustion Transcriptional Nodes
BATF, TBX21
Responsiveness or Response Biomarkers
Enhanced Expression in Responsive Versus Nonresponsive Cancers
APP, CAPZB, CCL4 (MIP-1B), CCL5 (RANTES), CD8A, CSNK1E, CTLA4, CXCL10 (INP10), CXCL11 (I-TAC, IP-9), CXCL9 (MIG), EBI3, EHD1, GBA2, GZMB, HLA-DQA1, IDO1 (IDO), IDO1 (IDO), IFNG, INHBA, IRF2, NKG7, ODF2, PHKG2, PPIF, PRF1, SERPINA3, SHMT2, SIGMAR1, SMAD3 (MADH3), TIA1
Suppressed Expression in Responsive Versus Nonresponsive Cancers
ACTG1, BNIP3L, CX3CL1, FOXN3, IFI27, JAK1, LTA4H, NAIP, OPTN, PRRC2B, PTEN, RBL2, TXK
Differentially Expressed in Responsive Versus Nonresponsive Cancers
ADAM28, AKNA, AOAH, ARHGAP9, CACNA2D2, CARD11, CARD16, CD109, CLEC11A, CORO1A, CORO1B, CXCR4, FLT3, FMNL1, HIVEP1, HIVEP2, IFI44L, IFITM1 (9-27), IGHA1, IGHM, IGSF6, IKZF1, ITPKA, LSM4, LST1, MAP3K14, NFAM1, NFKBIL1, PLA2G2D, POU2AF1 (OCA-B), PTPRCAP, SERPINB9, SH3BP5, SYTL1, TMC8, TNFRSF13B, TNFRSF19, ZFYVE9
Expression Correlates with Positive Objective Response Rates
CD274 (PD-L1), CD274 (PD-L1), CD276, CTLA4, HAVCR2, IDO1 (IDO), IDO1 (IDO), LAG3, PDCD1LG2, VTCN1
Upregulated during Treatment
CD8A, CTLA4, CXCL10 (INP10), EOMES, GZMA, GZMB, ICOS, IFNG, PRF1
Regulated during Treatment
IRF1
Pre-Treatment Response Prediction
Predicts Enhanced Response
ADAM17 (CD156B), MYC, RHOC, TIMP1
Other Pre-Treatment Response Predictors
CDK2, CDKN2A (P16INK4A), LARGE1, NAB2, NRAS
Cancer Cell Killing
Inhibits Cancer Cell Killing
BTLA, CD274 (PD-L1), CD274 (PD-L1), CD80, HAVCR2, IDO1 (IDO), IDO1 (IDO), IDO2, LAG3, MICA, MICB, PDCD1 (PD1), PDCD1 (PD1), TGFB1, VSIR, VTCN1
Stimulates Cancer Cell Killing
IFNG
Antigen Processing & Presentation
Proteasome
PSMB10, PSMB9
Proteases
IFI30
Endoplasmic Reticulum & Lysosomal Transport
TAP1 (ABCB2), TAP2 (ABCB3), TAPBPL
Major Histocompatibility Complex I Genes
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1
Major Histocompatibility Complex II Genes
CD74, HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
Immune Cell Receptors & Co-Receptors
CD8A, CD8B, KIR3DL1, KLRC1, KLRD1
Stimulates Antigen Presentation
CD40 (TNFRSF5), CD40LG
Interferon Gamma Response
Cytokines & Chemokines
CCL5 (RANTES), IL15RA, STAT1
Major Histocompatibility Complex I Genes
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H
Major Histocompatibility Complex II Genes
HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
RNA Degradation
OAS3
Transcription Factors
IRF1, IRF2
Other Interferon Gamma Response Genes
CD44, GBP1
Cytosolic DNA-Sensing Pathway
Cytokines & Interferons
CCL4 (MIP-1B), CCL5 (RANTES), CXCL10 (INP10)
Expression Altered due to Genetic Alterations
BCL10, BCL2, BCL3, BCL6, BCL9, CCND1, CCND2, CCND3, CD44, CDK6, ERVW-1, FCGR2B, FCRL4, FOXP1, GPR34, IRF4, KDSR, MALT1, MTCP1, MUC1 (mucin), MYC, NBEAP1, NFKB2, PAX5, PRDM16
AIDS-Related Lymphomas
EZH2
B Cell Lymphomas
ARID1A, ATM, B2M, BCL2, BCOR, BRAF, CD79B, CDKN2A (P16INK4A), CREBBP (CBP), CTNNB1, CXCR4, DNMT3A, EZH2, JAK3, KIT (CD117), KMT2D, MAP2K1, MYD88, PIK3CA (p110-alpha), PPM1D, PTEN, RHOA, STAT3
Small Lymphocytic Lymphomas
ALK, APC, ARID1A, ASXL1, ATM, BCL2, BCOR, BRAF, BTK, CD79B, CDKN2A (P16INK4A), CNOT3, CREBBP (CBP), CXCR4, DNMT3A, FBXW7, GNAS, IRS4, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MAP2K1, MED12, MSN, MYC, MYD88, NCOR1, NFKBIE, NOTCH2, NRAS, PAX5, PIK3CA (p110-alpha), PIK3R1 (p85-ALPHA), PLCG1, POT1, PPM1D, PTEN, RGS7, SF3B1, STAT5B, STAT6, TERT, TRRAP, XPO1, ZFHX3, ZMYM3, ZNF479
Cutaneous T Cell Lymphomas
KRAS, PTEN
Diffuse Red Pulp Small B Cell Lymphomas
MYD88, NOTCH2
Enteropathy-Type T Cell Lymphomas
STAT5B
Gamma-Delta T Cell Lymphomas
STAT3, STAT5B
Hepatosplenic T Cell Lymphomas
STAT3, STAT5B
Lymphoplasmacytic Lymphomas
ARID1A, BTK, CD79B, CXCR4, DNMT3A, MYD88
Marginal Zone Lymphomas
AMER1, ARID1A, ASXL1, ATM, BRAF, CD79B, CREBBP (CBP), CXCR4, DNMT3A, EZH2, FBXW7, GNAS, JAK3, KIT (CD117), KMT2D, MAP2K1, MYD88, NFKBIE, NOTCH2, PIK3R1 (p85-ALPHA), RHOA, SRSF2, TRRAP, XPO1
Mycosis Fungoides (Sezary Syndrome)
AMER1, ARID1A, ATM, BCOR, CDKN2A (P16INK4A), DNMT3A, JAK1, JAK3, KMT2D, KRAS, NCOR1, NRAS, PIK3CA (p110-alpha), PLCG1, POT1, PTEN, STAT3, STAT5B
NK-T Cell Lymphomas
ALK, AMER1, APC, ARID1A, ASXL1, ATM, B2M, BCOR, BRAF, CTNNB1, DNMT3A, EZH2, FBXW7, HLA-A, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MED12, NCOR1, NOTCH2, NRAS, POT1, RGS7, RHOA, SMO, STAT3, STAT5B, WT1, XPO1, ZFHX3
Primary Central Nervous System Lymphomas
B2M, BCL2, CD79B, CDKN2A (P16INK4A), CXCR4, DNMT3A, HLA-A, JAK3, KIT (CD117), KRAS, MYD88, NOTCH2, POT1, STAT3, STAT5B, TERT, TRRAP, WT1
Primary Effusion Lymphomas
CDKN2A (P16INK4A), PTEN